HomeCompareABSCF vs CL

ABSCF vs CL: Dividend Comparison 2026

ABSCF yields 137.93% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABSCF wins by $16.41M in total portfolio value
10 years
ABSCF
ABSCF
● Live price
137.93%
Share price
$1.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16.45M
Annual income
$6,780,916.45
Full ABSCF calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — ABSCF vs CL

📍 ABSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABSCFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABSCF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABSCF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABSCF
Annual income on $10K today (after 15% tax)
$11,724.14/yr
After 10yr DRIP, annual income (after tax)
$5,763,778.98/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, ABSCF beats the other by $5,759,187.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABSCF + CL for your $10,000?

ABSCF: 50%CL: 50%
100% CL50/50100% ABSCF
Portfolio after 10yr
$8.25M
Annual income
$3,393,159.20/yr
Blended yield
41.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ABSCF
No analyst data
Altman Z
-1.3
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABSCF buys
0
CL buys
0
No recent congressional trades found for ABSCF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABSCFCL
Forward yield137.93%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$16.45M$40.8K
Annual income after 10y$6,780,916.45$5,401.96
Total dividends collected$15.13M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ABSCF vs CL ($10,000, DRIP)

YearABSCF PortfolioABSCF Income/yrCL PortfolioCL Income/yrGap
1← crossover$24,493$13,793.10$11,012$312.01+$13.5KABSCF
2$57,781$31,573.45$12,196$412.95+$45.6KABSCF
3$131,437$69,611.34$13,599$549.66+$117.8KABSCF
4$288,626$147,988.71$15,288$736.64+$273.3KABSCF
5$612,543$303,712.69$17,353$995.28+$595.2KABSCF
6$1,257,814$602,392.61$19,926$1,357.80+$1.24MABSCF
7$2,501,908$1,156,047.28$23,194$1,873.82+$2.48MABSCF
8$4,826,093$2,149,051.62$27,439$2,621.52+$4.80MABSCF
9$9,038,168$3,874,248.32$33,088$3,727.38+$9.01MABSCF
10$16,451,756$6,780,916.45$40,806$5,401.96+$16.41MABSCF

ABSCF vs CL: Complete Analysis 2026

ABSCFStock

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Full ABSCF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ABSCF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABSCF vs SCHDABSCF vs JEPIABSCF vs OABSCF vs KOABSCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.